Stocktoria

Immunome Inc. IMNM

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-10-02

Immunome Inc. statistics & valuation

Market cap$2.3B
P / B3.6×
Net margin-3060.0%
Return on equity-33.5%
FCF margin-2890.1%
Return on capital-35.1%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-761.90% -3240.40% -3060.00% 2019202020212022202320242025
Gross margin (%)
2019202020212022202320242025
Operating margin (%)
-781.40% -3382.40% -3228.80% 2019202020212022202320242025
Return on equity (%)
-43.10% -51.30% -221.60% -89.10% -161.70% -33.50% 2019202020212022202320242025
Shares outstanding
1.1M 10.6M 12.1M 12.1M 43.3M 64.5M 113.1M 2019202020212022202320242025
Net debt ($)
-$39.3M 2019202020212022202320242025
Share buybacks ($)
2019202020212022202320242025
Return on assets (%)
-206.40% -40.10% -42.70% -153.40% -71.90% -121.90% -31.10% 2019202020212022202320242025
Free cash flow margin (%)
-59.90% -1304.80% -2890.10% 2019202020212022202320242025
Debt / equity (×)
0.01× 2019202020212022202320242025
EPS ($)
-$5.26 -$2.14 -$3.09 -$5.38 -$5.00 -$2.43 2019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating margin-3228.8%-3382.4%-781.4%————
Net margin-3060.0%-3240.4%-761.9%————
FCF margin-2890.1%-1304.8%-59.9%————
Return on assets-31.1%-121.9%-71.9%-153.4%-42.7%-40.1%-206.4%
Return on equity-33.5%-161.7%-89.1%-221.6%-51.3%-43.1%29.3%
Debt / equity—————0.01×—
Current ratio14.694.086.633.095.8214.121.88

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.